Fulminant hepatitis after grand mal seizures: Mechanisms and role of liver transplantation

Hepatology

Volumn 38, Issue 2, 2003, Pages 443-451

  Ichai, Philippe ^a,c   Huguet, Emmanuel ^a   Guettier, Catherine ^a   Azoulay, Daniel ^a   Gonzalez, Maria Eugenia ^a   Fromenty, Bernard ^b   Masnou, Pascal ^a   Saliba, Faouzi ^a   Roche, Bruno ^a   Zeitoun, Fahed ^a   Castaing, Denis ^a   Samuel, Didier ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b BEAUJON HOSPITAL   (France)

^c HÔPITAL PAUL BROUSSE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; BLOOD CLOTTING FACTOR 5;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; DISEASE COURSE; FATTY LIVER; FEMALE; GRAND MAL SEIZURE; HEPATITIS; HISTOLOGY; HUMAN; HYPOXIA; LIVER FAILURE; LIVER FUNCTION; LIVER NECROSIS; LIVER TRANSPLANTATION; MALE; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL;

EID: 0041764969     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2003.50327     Document Type: Article

References (46)

1. Lowenstein DH, Alldredge BK. Status epilepticus. N Engl J Med 1998;338:970-976.
2. Trey C, Davidson CS. In: Popper H and Shaffner F, eds. Progress in Liver Diseases: The Management of Fulminant Hepatic Failure. Grune and Stratton, New York and London: Heinemann, 1970;3:282-298.
3. Bismuth H, Samuel D, Castaing D, Adam R, Saliba F, Johan M, Azoulay D, et al. Orthotopic liver transplantation in fulminant and subfulminant hepatitis. The Paul Brousse experience. Ann Surg 1995;222:109-119.
4. Bernuau J, Goudeau A, Poynard T, Dubois F, Lesage G, Yvonnet B, Degott C, et al. Multivariate analysis of prognostic factors in fulminant hepatitis B. HEPATOLOGY 1986;6:648-651.
5. Bernuau J, Samuel D, Durand F. Criteria for emergency liver transplantation in patients with acute viral hepatitis and factor V below 50% of normal: a prospective study [Abstract]. HEPATOLOGY 1991;14:49A.
6. Ishak KG, Baptista A, Bianchi L, De Groote J, Gudat F, Denk H, Desmet V, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-699.
7. Brown SW, Clarke MA, Tomlin PI. Fatal liver failure following generalized tonic-clonic seizures. Seizure 1992;1:75-77.
8. Ussery XT, Henar EL, Black DD, Berger S, Whitington PF. Acute liver injury after protracted seizures in children. J Pediatr Gastroenterol Nutr 1989;9:421-425.
9. Decell MK, Gordon JB, Silver K, Meagher-Villemure K. Fulminant hepatic failure associated with status epilepticus in children: three cases and a review of potential mechanisms. Intensive Care Med 1994;20:375-378.
10. Smith DW, Cullity GL, Silberstein EP. Fatal hepatic necrosis associated with multiple anticonvulsant therapy. Aust N Z Med 1988;18:575-581.
11. Henrion J. Ischemia/reperfusion injury of the liver: pathophysiologic hypotheses and potential relevance to human hypoxic hepatitis. Acta Gastroenterol Belg 2000;63:336-347.
12. Henrion J, Descamps O, Luwaert R, Schapira M, Parfonry A, Heller F. Hypoxic hepatitis in patients with cardiac failure: incidence in a coronary care unit and measurement of hepatic blood flow. J Hepatol 1994;21:696-703.
13. Mohacsi P, Meier B. Hypoxic hepatitis in patients with cardiac failure. J Hepatol 1994;21:693-695.
14. Henrion J, Luwaert R, Collin L, Schmitz A, Schapira M, Heller R. Hypoxic hepatitis. Prospective, clinical and hemodynamic study of 45 cases. Gastroentérol Clin Biol 1990;14:836-841.
15. Henrion J, Schapira M, Heller FR. Ischemic hepatitis: the need for precise criteria. J Clin Gastroenterol 1996;22:126-130.
16. Flejou JF, Degott C, Capron JP. Microvesicular steatosis. Gastroentérol Clin Biol 1987;11:115-118.
17. Jezequel AM, Librari ML, Mosca P, Novelli G, Lorenzini I, Orlandi F. Changes induced in human liver by long-term anticonvulsant therapy. Liver 1984;4:307-317.
18. Pamperl H, Gradner W, Fridrich L, Pointner H, Denk H. Influence of long-term anticonvulsant treatment on liver ultrastructure in man. Liver 1984;4:294-330.
19. Baillie J, Baillie TA. Re: Incidental microvesicular steatosis due to valproic acid anticonvulsant therapy. Am J Gastroenterol 1992;86:1225-1226.
20. Scott DA, Gholson CF, Netchvolodoff CV, Ray M, Gonzalez E, Bacon BR. Incidental microvesicular steatosis due to valproic acid anticonvulsant therapy. Am J Gastroenterol 1991;86:500-502.
21. Selzner M, Rüdiger HA, Sindram D, Madden J, Clavien PA. Mechanisms of ischemic injury are different in the steatotic and normal rat liver. HEPATOLOGY 2000;32:1280-1288.
22. Koneru B, Reddy MC, Dela Torre AN, Patel D, Ippolito T, Ferrante RJ. Studies of hepatic warm ischemia in the obese zucker rat. Transplantation 1995;59:942-946.
23. Soltys K, Dikdan G, Koneru B. Oxidative stress in fatty livers of obese Zucker rats: rapid amelioration and improved tolerance to warm ischemia with tocopherol. HEPATOLOGY 2001;34:13-18.
24. Sohal RS, Weindruch R. Oxidative stress, caloric restriction and aging. Science 1996;273:59-63.
25. Raschid A, Wu TC, Huang CC, Chen CH, Lin HZ, Yang SQ, Lee FYJ, et al. Mitochondrial proteins that regulate apoptosis and necrosis are induced in mouse fatty liver. HEPATOLOGY 1999;29:1131-1138.
26. Galle PR. Apoptosis in liver disease. J Hepatol 1997;27:405-412.
27. Binek J, Hany A, Egloff B, Heer M. Acute fatal liver insufficiency due to valproic acid therapy. Schweiz Med Wochenschr 1991;121:228-233.
28. Kaufman KR. Carbamazepine, hepatotoxicity, organic solvents, and paints. Seizure 1999;8:250-252.
29. Puente M, Plaza S, Sanz MJ, Garcia B, de Juana P, Bermejo T. Increase in serum carbamazepine concentrations after acute viral hepatitis. Ann Pharmacother 1998;32:1369-1370.
30. Martinez P, Gonzalez de Etxabarri S, Ereno C, Lopez G, Hinojal C, Teira R. Acute severe hepatic insufficiency caused by carbamazepine. Rev Esp Enferm Dig 1993;84:124-126.
31. Morales-Diaz M, Pinilla-Rosa E, Ruiz I. Suspected carbamazepine-induced hepatotocicity. Pharmacotherapy 1999;19:252-255.
32. Dreifuss FE. Valproic acid hepatic fatalities: revised table. Neurology 1989;39:1558.
33. Sauve G, Bresson-Hadni S, Prost P, Le Calvez S, Becker MC, Galmiche J, Carbillet JP, et al. Acute hepatitis after Lamotrigine administration. Dig Dis Sci 2000;45:1874-1877.
34. Makin AJ, Fitt S, Williams R, Duncan JS. Fulminant hepatitis failure induced by lamotrigine. BMJ 1995;331:291.
35. Arnon R, De Vivo D, Defelice AR, Kazlow PG. Acute hepatic failure in a child treated with lamotrigine. Pediatr Neurol 1994;18:251-252.
36. Yuen AWC, Bihari DJ. Multiorgan failure and disseminated intravascular coagulation in severe convulsive seizures. Lancet 1992;340:618.
37. Brodie MJ. Lamotrigine. Lancet 1992;339:1397-1400.
38. Richardson CE, Williams DW, Kingham JGC. Gabapentin induced cholestasis. BMJ 2002;325:635.
39. Krishnamurthy KB, Drislane FW. Relapse and survival after barbiturate anesthesic treatment of refractory status epilepticus. Epilepsia 1996;37:863-867.
40. Claassen J, Hirsch LJ, Emerson RG, Mayer SA. Treatment of refractory status epilepticus with penthiobarbital, propofol, or midazolam: a systematic review. Epilepsia 2002;43:146-153.
41. Logroscino G, Hesdorffer DC, Cascino G, Annegers JF, Hauser WA. Short-term mortality after a first episode of status epilepticus. Epilepsia 1997;38:1344-1349.
42. Waterhouse EJ, Garnett LK, Towne AR, Morton LD, Barnes T, Ko D, DeLorenzo RJ. Prospective population-based study of intermittent and continuous convulsive status epilepticus in Richmond, Virginia. Epilepsia 1999;40:752-758.
43. Shorvon S. Status epilepticus: Its clinical features and treatment in children and adults. In: Handbook of Epilepsy Treatment. Cambridge, UK: Cambridge University Press, 1999;173-194.
44. Lowenstein DH, Alldredge BK. Status epilepticus at an urban public hospice in the 1980s. Neurology 1993;43:483-488.
45. Towne AR, Pellock JM, Ko D, DeLorenzo RJ. Determinants of mortality in status epilepticus. Epilepsia 1994;35:27-34.
46. Claassen J, Hirsch LJ, Emerson RG, Bates JE, Thompson TB, Mayer SA. Continuous EEG monitoring and midazolam infusion for nonconvulsive refractory status epilepticus. Neurology 2001;57:1036-1042.